CSBio CSBio

X
[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo, Mitsubishi UFJ Capital & Nagoya Institute of Technology Collaborate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Daiichi Sankyo"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            In a project under TaNeDS, Nagoya Institute of Technology discovered that a highly active, novel photoresponsive protein2 could be applied to the restoration of vision.

            Lead Product(s): GtCCR4

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY